Search

Your search keyword '"Ochsenbein AF"' showing total 101 results

Search Constraints

Start Over You searched for: Author "Ochsenbein AF" Remove constraint Author: "Ochsenbein AF"
101 results on '"Ochsenbein AF"'

Search Results

1. Combined mTOR inhibition and chemotherapy as an effective strategy to treat KRAS-mutant lung cancer

11. Quantification of fetomaternal hemorrhage by fluorescence microscopy is equivalent to flow cytometry.

13. IL-21/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy.

14. IL-9 secreted by leukemia stem cells induces Th1-skewed CD4+ T cells, which promote their expansion.

15. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.

16. Author Correction: Tumour mutations in long noncoding RNAs enhance cell fitness.

17. Molecular and immunological mechanisms of clonal evolution in multiple myeloma.

18. IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways.

19. Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

20. Tumour mutations in long noncoding RNAs enhance cell fitness.

21. MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma.

22. Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.

23. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.

24. Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities.

25. Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells.

26. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.

27. Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia.

28. LIGHT/LTβR signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells.

29. Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study.

30. Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells.

31. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.

32. Genetic Alterations Impact Immune Microenvironment Interactions in Follicular Lymphoma.

33. TNIK signaling imprints CD8 + T cell memory formation early after priming.

34. CD8 + T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia.

35. T-cell-Secreted TNFα Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer.

36. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.

37. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).

38. T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.

39. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.

40. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

41. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia.

42. TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis.

43. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.

44. Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells.

45. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling.

46. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.

47. CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis.

48. Regulation of hematopoietic and leukemic stem cells by the immune system.

49. Microbiota-derived compounds drive steady-state granulopoiesis via MyD88/TICAM signaling.

50. Cytotoxic CD8+ T cells stimulate hematopoietic progenitors by promoting cytokine release from bone marrow mesenchymal stromal cells.

Catalog

Books, media, physical & digital resources